San Diego, Calif. – An experimental treatment made from a plant virus is effective at protecting against a broad range of metastatic cancers in mice, shows a new study from the University of California San Diego. The treatment, composed of nanoparticles fashioned from the cowpea mosaic virus—a virus that infects...
Latest News
Basel, Switzerland – When cells become tumor cells, their metabolism changes fundamentally. Researchers at the University of Basel and the University Hospital Basel have now demonstrated that this change leaves traces that could provide targets for cancer immunotherapies. Cancer cells function in turbo mode: Their metabolism is programmed for rapid...
Fukui, Japan – Cancer is a leading cause of death globally. One of the primary reasons why cancer is such a deadly disease is the ability of cancer cells to become drug-resistant. After decades of medical research, scientists came to understand that malignant tumors often harbor a special population of...
Washington, D.C.—Legionnaires’ disease (LD), a rare and severe type of pneumonia, is a respiratory infection caused by species of Legionella bacteria. One of the most accurate ways to diagnose LD is to perform culture on samples from a patient’s lower respiratory tract, but those samples are difficult to obtain. In...
Basel – Novartis today announced new data that reinforce the transformational benefit of Zolgensma® (onasemnogene abeparvovec), an essential one-time treatment for spinal muscular atrophy (SMA). The overall safety profile remains favorable following presymptomatic treatment, in the long-term follow-up period from clinical studies and in the real-world setting. These data were...
Basel – Novartis today announced data that reinforce the transformational benefit of Zolgensma® (onasemnogene abeparvovec), an essential, one-time treatment and the only gene therapy for spinal muscular atrophy (SMA). New late-breaker data from the completed two-copy cohort of the Phase 3 SPR1NT clinical trial demonstrate age-appropriate milestone development in presymptomatic children...
Chapel Hill, North Carolina – UNC Health is now enrolling patients as part of a multicenter clinical trial for patients who have been newly diagnosed with glioblastoma (GBM). The phase 2b clinical study administers IGV-001, a combination immunotherapy developed by biotech company Imvax. UNC Health is one of multiple academic...
ZURICH, Switzerland – Fatigue is common in people with inflammatory rheumatic and musculoskeletal diseases (RMD). The causes of fatigue are not well understood, and it is likely that they vary between people and over time. From a patient perspective, fatigue has a significant and detrimental impact on daily life, and...
INDIANAPOLIS, Indiana — A new study led by Indiana University School of Medicine researchers found a brain network condition called “explosive synchronization” could be the cause of extreme pain crises in people with sickle cell disease. “These findings could have a significant impact on patients with this disease,” said Ying Wang,...
LOS ANGELES, Calif. – A previously unidentified genetic mutation in a small protein provides significant protection against Parkinson’s disease and offers a new direction for exploring potential treatments, according to a new USC Leonard Davis School of Gerontology study. The variant, located in a mitochondrial microprotein dubbed SHLP2, was found...